Walmart.com/AOL NEW YORK -- Treadmills for $33? Computer monitors for $9? The deals are too good to be true -- even at Walmart. It turns out they're not. Walmart Stores Inc. (WMT) says a "technical error" caused certain products to be priced absurdly low or high on its website earlier Wednesday morning. The company said it's working to resolve the issue and that the site may have intermittent problems with availability until then. "We apologize for any inconvenience to our customers," said Ravi Jariwala, a spokesman for Walmart's online operations. Earlier Wednesday, shoppers took to Twitter to cite ridiculously low prices like treadmills for $33.16 and Hewlett Packard LCD monitors for $8.85. Jariwala declined to comment on whether it would honor bargains that customers scooped up and said it was still working through the details. Heading into the crucial holiday shopping season, Walmart has doubled the number of items it has on its website from last year to 5 million. That's expected to help fuel a 30 percent growth in online sales to $10 billion for its current fiscal year, which ends in late January. That's still just a sliver of the $486 billion in annual sales Walmart did last year. Walmart is based in Bentonville, Ark. We're not saying you should give up shopping on Black Friday altogether. Just do it online instead. At one point it may have been true that Black Friday was for in-store deals, while Cyber Monday was for the e-commerce set. But these days, retailers are taking pains to offer a seamless experience between their online and bricks-and-mortar channels, and that means many of the marquee Black Friday deals can be had from the comfort of your couch. "[Retailers] continue to get better at syncing the online and offline experience," says Brad Wilson of BradsDeals. "95 percent-plus of deals are going to be available both online and offline."
Best Dow Dividend Stocks To Watch Right Now: Horizon Pharma Inc (HZNP)
Horizon Pharma, Inc. (Horizon), incorporated on March 23, 2010, is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. On April 23, 2011, the United States Food and Drug Administration, approved DUEXIS (formerly HZT-501), a tablet formulation containing a fixed-dose combination of ibuprofen and famotidine in a single pill. The Company�� other product, LODOTRA (NP-01), is a programmed release formulation of low-dose prednisone that is marketed in Europe by the Company�� distribution partner, Mundipharma International Corporation Limited (Mundipharma). As of December 31, 2010, Horizon completed multiple Phase III clinical trials of LODOTRA. In addition to these product candidates, the Company has a pipeline of earlier-stage product candidates to treat pain-related diseases and chronic inflammation. On April 1, 2010, Horizon effected a recapitalization and acquisition pursuant to which Horizon Pharma, Inc. became a holding company, that operates through its wholly owned subsidiaries, Horizon Pharma USA, Inc. (formerly Horizon Therapeutics, Inc.) and Horizon Pharma AG (formerly Nitec Pharma AG (Nitec)).
DUEXIS
DUEXIS is a combination of 800 milligram ibuprofen and 26.6 milligram famotidine in a single pill and is indicated for the relief of signs and symptoms of rheumatoid arthritis (RA), and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal (GI), ulcers in patients who are taking ibuprofen for those indications. The Company has completed two Phase III clinical trials in a total of over 1,500 patients with mild to moderate pain or arthritis that demonstrated a significant reduction in the incidence of non-steroidal anti-inflammatory drugs (NSAID)-induced upper GI ulcers when treated with DUEXIS versus ibuprofen alone.
LODOTRA
LODOTRA is a programmed release formulation of low-dose prednisone, a well-established drug use! d to inhibit the production of various pro-inflammatory cytokines, which are proteins associated with joint inflammation in RA. LODOTRA has received regulatory approval in Europe for the treatment of moderate to severe, active RA in adults when accompanied by morning stiffness. As of December 31, 2010, the Company had completed two pivotal Phase III clinical trials of LODOTRA in a total of over 600 patients with RA. The first pivotal Phase III trial supported the approval of LODOTRA in Europe in March 2009, where it is approved for marketing in 14 European countries. LODOTRA achieved significant results and met the primary endpoint in each of the two pivotal Phase III clinical trials. Its LODOTRA product was developed and is owned by Horizon Pharma AG. As of December 31, 2010, the Company markets LODOTRA in Europe through three separate agreements. Pursuant to two separate agreements, it granted Merck Serono GmbH and Merck GesmbH, an affiliate of Merck Serono, the rights to distribute and market LODOTRA in each of Germany and Austria, respectively, and pursuant to the third agreement, it granted Mundipharma rights to distribute and market LODOTRA in the rest of Europe. The Company also has a manufacturing and supply agreement with Jagotec AG under which Jagotec or its affiliates manufacture and supply LODOTRA to the Company as bulk tablets.
The Company competes with Pfizer Inc., Pozen Inc., Abbott Laboratories and Amgen Inc.
Advisors' Opinion:- [By Bryan Murphy]
After a 16% rally on Tuesday, it would be understandable is a newcomer wanted to steer clear of Horizon Pharma Inc. (NASDAQ:HZNP). After all, how much more upside can there be for this fairly typical small cap biotech stock. Yet, HZNP may well be one of the rare exceptions to the "tough to follow-through" tendency.
For those not familiar, HZNP is a biopharma name with a couple of rheumatoid arthritis, COPD, and asthma drugs on the market... Duexis, and Rayos. There's a third drug in the pipeline - Lodotra, for polymyalgia rheumatica, though it's already approved as a treatment for RA.� Either way, Horizon Pharma Inc. is unique in the sense that though it's a small biopharma company, it's at least driving revenue with a handful of marketable products.
The pipeline and portfolio are secondary at this point, however. What matters most to traders now is whether or not there's actually any upside left to tap into with Horizon Pharma. The answer is, it depends.
Given just the nearby daily chart, no, it looks like HZNP has burned up all of its fuel. Aside from the fact that it's overextended now, Tuesday's volume spike also implies anybody who was thinking about buying went ahead and took the plunge. That may well mean nobody is left to keep buying tomorrow. There may well be, however, plenty of nervous-Nellie profit-takers ready to head for the exit.
The assessment changes quite a bit when you zoom out to a longer-term chart of Horizon Pharma, though.
While this won't allow the stock to sidestep a near-term pullback, Tuesday's pop was something a game-changer for the long-term chart. The move shook the stock out of a narrow range that had trapped the stock between $2.80 and $2.12 for the last ten months.
The proverbial "so what" is, with nearly a years' worth of pent-up energy finally being unleashed, we're nowhere near the end of the final resting place. Once we burn off this initial, knee-jerk reaction to the
Top 5 Low Price Companies To Invest In 2014: Nam Tai Electronics Inc.(NTE)
Nam Tai Electronics, Inc. provides electronics manufacturing and design services to the original equipment manufacturers of telecommunication and consumer electronic products. The company?s Consumer Electronic and Communication Products segment manufactures mobile phone accessories, such as headsets containing Bluetooth wireless technology, and phone cradles, as well as snap-on portable music speaker, FM radio adaptors, and GPS adaptors; entertainment devices, including USB Web cam for interactive games, USB microphone and converter box Karaoke, and buzzer devices for quiz games; educational products consisting of digital pens, calculators, and electronic dictionaries; and optical devices comprising CMOS imaging sensor modules for notebook computers, portable media players, and recording cameras for the automotive industry. Its Telecommunication Component Assembly segment offers subassemblies and components, such as color and monochrome LCD modules for PDA phones, smart p hones, mobile phones, and telephone systems; RF modules for integration into mobile phones; DAB modules for digital radio products, including home tuners, kitchen radios, in-car receivers, CD players, clock radios, boom boxes, midi-systems, and handheld portable devices; FPC subassemblies for LCD modules and electronic devices; FPC boards for mobile phones, PDAs, office automation, and laptop computers; front and back light panels for handheld video game devices; and high-frequency cordless telephones and home feature phones. The company?s LCD Products segment manufactures LCD panels for watches and medical instruments, white goods and industrial applications, automotive parts and appliances, car audio systems, hand held products, VoIP phones, and office automation applications. It sells its products to customers in Hong Kong, North America, Europe, Japan, the People?s Republic of China, and Korea. The company was founded in 1975 and is headquartered in Shenzhen, the Peopl e?s Republic of China.
Advisors' Opinion:- [By Rick Munarriz]
Nam Tai Electronics� (NYSE: NTE ) -- $6.78
Shares of Nam Tai took a hit three months ago after posting uninspiring quarterly results. - [By Evan Niu, CFA]
What: Shares of Nam Tai Electronics (NYSE: NTE ) got crushed today by as much as 37% after the company reported earnings.
So what: Revenue in the first quarter more than doubled to $177.5 million, which translated into earnings per share of $0.11. Both figures handily topped consensus estimates, which were calling for $150 million in sales and $0.05 per share in profit. The real cause for concern was within Nam Tai's guidance.
Top 5 Low Price Companies To Invest In 2014: Powershares DB Commodity Index Tracking Fund (DBC)
PowerShares DB Commodity Index Tracking Fund (the Fund) and its subsidiary, DB Commodity Index Tracking Master Fund (the Master Fund), were formed as trusts. The Fund is designed to replicate positions in a commodity index.
The PowerShares DB Commodity Index Tracking Fund is based on the Deutsche Bank Liquid Commodity Index - Optimum Yield Excess Return (Index). The Fund is managed by DB Commodity Services LLC.
Advisors' Opinion:- [By Cameron Swinehart]
Going forward I will be looking to add investments on my watchlist and trim other positions. It will be interesting to see how an overweight commodity portfolio will perform relative to the rest of the market.
Cost Basis# SharesCurrent Price% of PortfolioCurrent ValueReturnMetal/Miners Sprott Physical Gold Trust (PHYS)$12.4985$11.043.75%$938.40-13.13%Sprott Physical Silver Trust (PSLV)$7.95125$8.744.37%$1,092.509.04%FreePort-McMoran (FCX)$31.6731$33.874.20%$1,049.976.50%Ishares MSCI Global Gold Miners ETF (RING)$13.0695$10.644.04%$1,010.80-22.74%Energy Statoil ASA(STO)$21.7940$22.683.63%$907.203.92%Vanguard Natural Resources LLC (VNR)$27.5636$27.874.01%$1,003.321.11%ConocoPhillips (COP)$63.6822.43$71.006.37%$1,592.5310.31%Agriculture CVR Partner LP (UAN)$26.3630.9$18.932.34%$584.94-39.25%Adecoagro$6.78125$7.443.72%$930.008.87%Archer-Daniels Midland (ADM)$34.8030$37.244.47%$1,117.206.55%Mixed Commodity Powershares DB Commodity Index (DBC)$26.3540$25.954.15%$1,038.00-1.54%Sprott Resource Corp$3.34400$2.714.34%$1,084.00-23.25% Total % of portfolio49.40% Cost Basis12,666.00 Current Value12,348.86 Return-2.50% Source: Investing For The Future Surge In Commodity PricesDisclosure: I am long ADM, FCX, UAN, AGRO, RING, VNR, SCPZF.PK, COP, DBC, PHYS, PSLV. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)
- [By Richard Stavros]
Another futures-based ETF is PowerShares Deutsche Bank Commodity Index (DBC). It is more diversified than DBA. It holds futures contracts in corn and wheat. But it also holds significant positions in gold, heating oil, and crude.
- [By Doug Fabian]
PowerShares DB Commodity Index Tracking Fund (DBC) is a fund that tracks a basket of commodities, including gold, silver, Brent crude oil, RBOB gasoline, heating oil, sugar, corn, soybeans, and much more.
Top 5 Low Price Companies To Invest In 2014: Constant Contact Inc.(CTCT)
Constant Contact, Inc. provides on-demand email marketing, social media marketing, event marketing, and online survey products primarily in the United States. It offers email marketing products, which allow customers to create, send, and track professional and affordable permission-based email marketing campaigns; and social media marketing products that allow customers to manage and optimize their presence across multiple social media networks. The company also provides event marketing products, which enable its customers to promote and manage events, communicate with invitees and registrants, capture and track registrations, and collect online payments; and online survey products that enable its customers to create and send surveys, and analyze the responses. In addition, it offers customer support services to customers and trailers through phone, chat, email, and social media. Further, the company provides ancillary services, such as custom services to customers who lik e its email campaigns, event promotions, or surveys prepared for them; and online training programs to educate participants on email marketing and social media marketing best practices, as well as a workshop programs. It markets its products directly for small organizations, including retailers, restaurants, law and accounting firms, consultants, non-profits, religious organizations, and alumni associations. The company was formerly known as Roving Software Incorporated and changed its name to Constant Contact, Inc. in 2006. Constant Contact, Inc. was founded in 1995 and is headquartered in Waltham, Massachusetts.
Advisors' Opinion:- [By Evan Niu, CFA]
What: Shares of Constant Contact (NASDAQ: CTCT ) have popped today by upwards of 19% after the company reported first-quarter earnings.
- [By Lisa Levin]
Constant Contact (NASDAQ: CTCT) shares rose 27.28% to $27.90. The volume of Constant Contact shares traded was 797% higher than normal. Constant Contact lifted its Q1 and FY14 revenue outlook.
No comments:
Post a Comment